MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6603-694-701$20.00
Mol Pharmacol 66:694-701, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, N.
Right arrow Articles by Klaassen, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, N.
Right arrow Articles by Klaassen, C. D.

Role of Liver-Enriched Transcription Factors in the Down-Regulation of Organic Anion Transporting Polypeptide 4 (Oatp4; Oatplb2; Slc21a10) by Lipopolysaccharide

Ning Li, and Curtis D. Klaassen

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas

Lipopolysaccharide (LPS) administration is a model of cholestasis. Organic anion transporting polypeptide 4 (Oatp4; Slc21a10) is almost exclusively expressed in liver. Therefore, it was hypothesized that LPS would down-regulate mouse Oatp4 and that this action is due to a decrease in nuclear binding activity of one or more liver-enriched transcription factors to mouse Oatp4 promoter. The present study indicates a time-dependent decrease in mouse Oatp4 mRNA levels by LPS. Moreover, LPS produced a rapid and profound decrease in nuclear binding activity to the mouse Oatp4 putative response elements for hepatocyte nuclear factor (HNF) 1, CAAT/enhancer binding protein (C/EBP), HNF3, and heterodimers of retinoid X receptor (RXR) and retinoic acid receptor (RAR). Maximal decrease in nuclear binding activity to these response elements preceded a significant reduction of Oatp4 mRNA levels. HNF1{alpha} bound to the Oatp4 HNF1 response element as a homodimer. Multiple copies of the Oatp4 HNF1{alpha} response element, inserted upstream of a minimal promoter, were sufficient to mediate reporter activity and responded to the coexpression of HNF1{alpha} in mouse hepatoma cells. Moreover, HNF1{alpha} dose dependently activated the Oatp4 promoter (–4.8 kilo-bases to +30 bp). Therefore, HNF1{alpha} is a potent trans-activator of the mouse Oatp4 promoter. In addition, Oatp4 mRNA levels were markedly decreased (95%) in HNF1{alpha}-null mice as compared with wild-type mice, suggesting that HNF1{alpha} levels are critical for the constitutive expression of the Oatp4 gene. Taken together, these findings suggest that the LPS-induced down-regulation of Oatp4 is likely due to reduction in the binding of HNF1{alpha}, C/EBP, HNF3, and RXR:RAR to the Oatp4 promoter.


Received January 29, 2004; accepted June 10, 2004

Address correspondence to: Dr. Curtis D. Klaassen, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160. E-mail: cklaasse{at}kumc.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
M. Wagner, G. Zollner, P. Fickert, J. Gumhold, D. Silbert, A. Fuchsbichler, J. S. Gujral, K. Zatloukal, H. Denk, H. Jaeschke, et al.
Hepatobiliary Transporter Expression in Intercellular Adhesion Molecule 1 Knockout and Fas Receptor-Deficient Mice after Common Bile Duct Ligation Is Independent of the Degree of Inflammation and Oxidative Stress
Drug Metab. Dispos., September 1, 2007; 35(9): 1694 - 1699.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Gu, S. Ke, D. Liu, T. Sheng, P. E. Thomas, A. B. Rabson, M. A. Gallo, W. Xie, and Y. Tian
Role of NF-{kappa}B in Regulation of PXR-mediated Gene Expression: A MECHANISM FOR THE SUPPRESSION OF CYTOCHROME P-450 3A4 BY PROINFLAMMATORY AGENTS
J. Biol. Chem., June 30, 2006; 281(26): 17882 - 17889.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics